A promising new cancer vaccine that has cured up to 97 percent of tumors in mice will soon be tested in humans for the first time – but experts say that we are still a long way from cancer patients in this type of prescribed medication  Researchers from Stanford University will test the therapy in about 35 people with Lymphoma by the end of the year, according to SFGate, a local news source in San Francisco. The treatment stimulates the body's immune system to attack cancer cells. In studies on mice with various types of cancer – including lymphoma, breast cancer and colorectal cancer – the treatment eradicated tumors in 87 out of 90 mice, even though the tumors had spread to other parts of the body, the researchers said.
Dr. Alice Police, the regional head of breast surgery at the Northwell Health Cancer Institute in Westchester, New York, who was not involved in the study, said the news of a human attempt to test this treatment was "exciting." However, she warned that results in animal experiments can not always be transferred to humans.
"We were able to cure a lot of cancer in mice for a long time," the police told Live Science. In addition, the current human studies are for patients with lymphoma, and so it could take many years for doctors to know if this treatment works for other cancers, such as breast and colon cancers, police said. [1
A cancer vaccine?
The new treatment is technically not a vaccine, a term used for substances that provide long-lasting immunity to disease. However, the treatment involves a vaccine-like injection, reports SFGate. (According to the American Society of Clinical Oncology, a "cancer vaccine" may refer to a treatment used to prevent cancer from returning and destroying cancer cells that are still in the body.)
Instead, the treatment is on Type of immunotherapy. It contains a combination of two drugs that stimulate T cells, a type of immune cell, to attack cancer. Normally, the body's own T cells recognize cancer cells as abnormal and will infiltrate and attack them. But when a tumor grows, it suppresses the activity of T cells so that these cells can no longer keep the cancer at bay.
The new treatment works by reactivating these T cells. Researchers inject the "vaccine" directly into the tumor. The two agents in the treatment work synergistically in the activation of T cells. Because these T cells were already inside the tumors, they were essentially "pre-screened" by the body to detect cancer-specific proteins, the researchers said.
In animal experiments, injection into just one tumor has tried to eliminate tumors in other parts of the body (so-called metastatic cancers). This happens because active T cells migrate to other parts of the body and destroy tumors that have spread.
In a study published January 31 in the journal, Science Translational Medicine, scientists treated mice that were genetically engineered to develop breast cancer in all 10 of their breast pads. The drug was injected into the first tumor found in the animal, and the researchers found that in many cases the treatment also prevented the onset of future tumors,
Immunotherapy is not new; In fact, several other immunotherapies have been approved for the treatment of cancer. For example, a treatment called CAR T-cell therapy, which has recently been approved for some types of leukemia and lymphoma, involves removing certain immune cells from the body of patients and genetically engineering these cells to fight cancer. Another advantage of the new therapy is that the doctors do not have to remove the immune cells of the patient to fight cancer, the researchers said. "We target specific targets without having to pinpoint exactly which proteins recognize T cells," Dr. Ronald Levy, professor of oncology at Stanford University's medical school and senior author of the study "Science Translational Medicine"
It's also interesting that the work could have implications for colon and breast cancer, two cancers for which there are currently There are no immunotherapies, the police said.
"We've taken [gone] one step down the road" to immunotherapy for these cancers, police said. "But it's a long way [still]."
The new study is a Phase I trial, meaning that it only tests the safety of the treatment and does not determine how effective it is.
Original article from Live Science .